Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00107198 · ClinicalTrials.gov registry record · Phase 2
Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease
A Phase 2 study of Ann Arbor Stage I Childhood Hodgkin Lymphoma and Ann Arbor Stage II Childhood Hodgkin Lymphoma, sponsored by Children's Oncology Group.
- Active
- Registry status
- Phase 2
- Development phase
- 188
- Enrollment target
- 20
- Study locations
NCT00107198: Active Phase 2 study of Ann Arbor Stage I Childhood Hodgkin Lymphoma and Ann Arbor Stage II Childhood Hodgkin Lymphoma, sponsored by Children's Oncology Group.
NCT00107198 is a Phase 2 study of Ann Arbor Stage I Childhood Hodgkin Lymphoma and Ann Arbor Stage II Childhood Hodgkin Lymphoma that is active but no longer recruiting, run by Children's Oncology Group. The registered enrollment target is 188 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (41% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00107198, a Phase 2 study of Ann Arbor Stage I Childhood Hodgkin Lymphoma and Ann Arbor Stage II Childhood Hodgkin Lymphoma, is active but no longer recruiting, sponsored by Children's Oncology Group.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 188 participants
- Enrollment target
- 20
- Study locations
Study Summary
This clinical trial is studying how well surgery and/or combination chemotherapy with or without radiation therapy or observation only work in treating young patients with newly diagnosed stage I or stage II lymphocyte predominant Hodgkin disease (LPHD). Surgery may be an effective treatment for LPHD. Drugs used in chemotherapy, such as doxorubicin, vincristine, prednisone, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill cancer cells. Giving more than one drug (combination chemotherapy) with or without radiation therapy may kill more cancer cells.
Primary Outcome
The time to a treatment (strategy) failure, where failure includes one of the following occurrences as a first event: disseminated disease (\> Stage I/II) progression or recurrence at any time, local disease progression or recurrence anytime during or after treatment with AV-PC +/- IFRT, occurrence of a second malignant neoplasm, death from any cause.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- RADIATION Radiation Therapy
- DRUG Doxorubicin Hydrochloride
- DRUG Prednisone
- PROCEDURE Conventional Surgery
Study Locations (20)
California
- Kaiser Permanente Downey Medical Center - Downey
- City of Hope Comprehensive Cancer Center - Duarte
- Miller Children's and Women's Hospital Long Beach - Long Beach
- Children's Hospital Los Angeles - Los Angeles
- UCSF Benioff Children's Hospital Oakland - Oakland
- Kaiser Permanente-Oakland - Oakland
- Children's Hospital of Orange County - Orange
- Sutter Medical Center Sacramento - Sacramento
- Rady Children's Hospital - San Diego - San Diego
- UCSF Medical Center-Mount Zion - San Francisco
- UCSF Medical Center-Parnassus - San Francisco
- Harbor-University of California at Los Angeles Medical Center - Torrance
Alabama
- Children's Hospital of Alabama - Birmingham
- University of Alabama at Birmingham Cancer Center - Birmingham
Arizona
- Phoenix Childrens Hospital - Phoenix
- Banner University Medical Center - Tucson - Tucson
Arkansas
- Arkansas Children's Hospital - Little Rock
- University of Arkansas for Medical Sciences - Little Rock
Colorado
- Children's Hospital Colorado - Aurora
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2006-01-02 |
| Est. Completion | 2030-12-31 |
| Phase | Phase 2 |
What the registry record for NCT00107198 still lists
NCT00107198 is an interventional study that assigns participants to a tested intervention. The registered 188 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (41% higher).
The record links to 3 conditions, with Ann Arbor Stage I Childhood Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00107198 names 20 study sites across 5 states, led by California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT00107198 about?
NCT00107198 is a clinical study titled "Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease". This clinical trial is studying how well surgery and/or combination chemotherapy with or without radiation therapy or observation only work in treating young patients with newly diagnosed stage I or stage II lymphocyte predominant Hodgkin disease (LPHD). Surgery may be an effective treatment for LPH...
What is the current status of trial NCT00107198?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 188 participants. The study started on 2006-01-02. Estimated completion is 2030-12-31.
What conditions does trial NCT00107198 study?
This clinical trial studies the following conditions: Ann Arbor Stage I Childhood Hodgkin Lymphoma, Ann Arbor Stage II Childhood Hodgkin Lymphoma, Childhood Nodular Lymphocyte Predominant B-Cell Lymphoma.
What interventions are being tested in trial NCT00107198?
The interventions under investigation include: Cyclophosphamide (DRUG), Radiation Therapy (RADIATION), Doxorubicin Hydrochloride (DRUG), Prednisone (DRUG), Conventional Surgery (PROCEDURE).
Who is sponsoring clinical trial NCT00107198?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00107198 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00107198's enrollment target sits among peer trials
188 356th of 2000 higher than 1,644 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422198 · 188 participants · Phase 3
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
- NCT04469790 · 188 participants · NA
Effects of Multi-day Interruptions in Sitting on Type 2 Diabetes-relevant Outcomes in Children
- NCT04671667 · 188 participants · Phase 2
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- NCT04853251 · 188 participants · Phase 4
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI